Evidence map›Paper›PMID 33082342›Full record

Trial reportNature communications2020

A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.

Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Corina Silvia Rueegg, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04316377 (Norwegian Coronavirus Disease 2019 Study), which is not on this map. Cited by 47 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 21 pooled it
1.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04316377 phase4unknown statusnot on this map

Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection

TypeinterventionalSponsorUniversity Hospital, AkershusRan2020 to 2025Enrolled53ConditionsCorona Virus InfectionArmsHydroxychloroquine Sulfate
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 21 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Guideline
  20. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Magnus Nakrem LyngbakkenDivision of Medicine, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0002-5994-9304
Jan-Erik BerdalInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Arne EskesenDepartment of Infectious Diseases, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
Dag KvaleInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-6410-2530
Inge Christoffer OlsenDepartment of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.
Corina Silvia RueeggDepartment of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-3720-4659
Anbjørg RangbergCenter for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.
Christine Monceyron JonassenCenter for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.
Torbjørn OmlandDivision of Medicine, Akershus University Hospital, Lørenskog, Norway.
Helge RøsjøInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. helge.rosjo@medisin.uio.no.ORCID 0000-0003-2114-3134
Olav DalgardInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NOØstfold Hospital Trust · NOAkershus University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.

Indexed as

AgedAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFemaleHumansHydroxychloroquineMaleMiddle AgedPandemicsPneumonia, ViralSARS-CoV-2Treatment OutcomeViral LoadAntiviral AgentsHydroxychloroquine

Identifiers

PMID33082342
PMCPMC7576792
OpenAlexW3092712522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.